MyFinsight
Home
Blog
About
Contact
Download
Download image
Maturities of marketable
debt securities
$81,662K
Net cash provided by
investing activities
$70,588K
Canceled cashflow
$11,074K
Net increase
(decrease) in cash and cash...
-$19,237K
Canceled cashflow
$70,588K
Accounts receivable
-$18,249K
Stock-based compensation
expense
$8,617K
Depreciation and
amortization
$3,857K
Non-cash interest
expense
$3,753K
Operating lease
right-of-use assets
-$1,705K
Prepaid expenses
-$384K
Accounts payable
$349K
Other non-cash
adjustments
-$19K
Proceeds from issuance of
common stock under...
$648K
Proceeds from exercise of
stock options
$146K
Purchases of marketable
debt securities
$9,839K
Purchases of property and
equipment
$1,235K
Net cash provided by
(used in) operating...
-$76,186K
Canceled cashflow
$36,933K
Net cash used in
financing activities
-$13,639K
Total research and
development expense
-$111,349K
Total general and
administrative expense
-$39,177K
Other segment items
-$16,567K
Cost of license and
royalty revenues
-$3,296K
Canceled cashflow
$794K
Net income (loss)
-$90,051K
Canceled cashflow
$170,389K
Accrued expenses and
other current...
-$16,734K
Operating lease
liabilities
-$2,525K
Other current assets
$1,314K
Other assets
$900K
Net accretion of
discounts on marketable...
$879K
Deferred revenue
-$700K
Other liabilities
-$16K
Repayments under royalty
monetization liabilities,...
$13,375K
Taxes paid related to
net settlement of...
$828K
Expenses related to
at-the-market offering...
$230K
Revenues
-$133,711K
something is missing
-$126,729K
Back
Back
Cash Flow
REGENXBIO Inc. (RGNX)
REGENXBIO Inc. (RGNX)
source: myfinsight.com